scholarly journals Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

2019 ◽  
Vol Volume 11 ◽  
pp. 10239-10248 ◽  
Author(s):  
Ruxu You ◽  
Jinyu Liu ◽  
David Bin-Chia Wu ◽  
XinYu Qian ◽  
Boxiang Lyu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Effectiveness Analysis ◽  
Line Therapy ◽  
Egfr Mutation Testing

scholarly journals Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer

Lung Cancer ◽  
2015 ◽  
Vol 90 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Yusuke Narita ◽  
Yukiko Matsushima ◽  
Takeru Shiroiwa ◽  
Koji Chiba ◽  
Yoichi Nakanishi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Effectiveness Analysis ◽  
Line Therapy ◽  
Egfr Mutation Testing
Sign in / Sign up

Export Citation Format

Share Document